Peptides - Compound guides
5-Amino-1MQ
Last reviewed 13 August 2026. How we write this .
5-Amino-1MQ is a small molecule that inhibits the enzyme NNMT in laboratory and animal studies. It is not a peptide and has essentially no human trial evidence.
Start here 5-Amino-1MQ is a small molecule that inhibits the enzyme NNMT in laboratory and animal studies. It is not a peptide and has essentially no human trial evidence.
By the end, you will understand How it is thought to work What the research actually shows Where the evidence stops Key words used in this lesson Peptide A short chain of amino acids joined together. The distinction from a protein is one of size rather than kind: chains shorter than roughly fifty amino acids are usually called peptides, longer ones proteins. Amino acid The individual building block of peptides and proteins. Twenty of them, combined in different orders, make up essentially all the protein in the human body. Preclinical Research done before any human testing, typically in cells and animals. The large majority of compounds that look promising preclinically never go on to work in people. Randomised controlled trial A study in which participants are assigned by chance to receive the intervention or a comparison, so that differences in outcome are less likely to be explained by who ended up in which group. The strongest single study design for testing whether something works. Purity The proportion of a sample that is the stated compound. A high purity figure says nothing about whether the remaining fraction is harmless, and nothing at all about whether the compound is safe or effective. Full plain-English glossary
Where this information comes from Preclinical evidence. The evidence discussed is mainly from laboratory or animal research and cannot establish benefit in people.
This lesson links the specific studies and guidance used for its central claims.
Our standard: expert or athlete opinion may illustrate a viewpoint, but it is never treated as proof. Read the editorial policy .
Report an error or outdated claim .
5-Amino-1MQ in plain English Marketed for fat loss and energy.
The idea: it blocks an enzyme called NNMT, and in obese mice blocking that enzyme reduced fat gain. So the pitch is that it changes how fat cells handle energy.
The catch: It is not a peptide, and it was never developed as a product for people - it was a laboratory tool for studying an enzyme. There is essentially no human trial evidence at all. Everything sold with it is extrapolated from mice.
5-Amino-1MQ is a small synthetic molecule - specifically a substituted quinolinium compound. It is worth being clear about this from the start, because it is almost always sold and discussed alongside peptides, and many people assume it is one. It is not. It has no amino acid chain and no peptide bonds. It is a small-molecule enzyme inhibitor, chemically much closer to a conventional drug candidate than to anything in the peptide category.
It was not developed as a consumer product. It came out of academic work on an enzyme called nicotinamide N-methyltransferase, or NNMT, published in the mid-2010s, where it was used as a chemical tool to test what happens when that enzyme is blocked in laboratory animals. It travelled from that narrow research context into the online supplement and research-chemical market largely on the strength of a single strand of mouse data.
How it is thought to work
NNMT is an enzyme found in many tissues, with particularly high activity in fat tissue and liver. Its job is to attach a methyl group to nicotinamide, a form of vitamin B3. This does two things that researchers found interesting. It consumes nicotinamide, which is a precursor the cell can otherwise use to make NAD+, a coenzyme central to energy metabolism. And it consumes methyl groups from S-adenosylmethionine, the cell's main methyl donor, which is involved in a wide range of regulatory processes including how genes are marked.
The hypothesis - and it is important to keep the word hypothesis attached - runs like this. If NNMT activity in fat tissue is high, it may be draining nicotinamide away from NAD+ production and altering the availability of methyl groups in ways that shift how fat cells handle energy. Inhibiting the enzyme might therefore change fat cell metabolism. 5-Amino-1MQ was used in animal studies as a way of testing that idea. It is a well-defined biochemical question, and it is genuinely interesting. It is also, at present, an idea supported almost entirely by work in cells and rodents.
What the research actually shows
The evidence here is preclinical, and it is important to say that plainly rather than softening it. The frequently cited work involved diet-induced obese mice given an NNMT inhibitor, in which the treated animals were reported to show reductions in fat mass and body weight relative to controls, alongside changes in metabolic markers. Subsequent laboratory work has continued to explore NNMT as a target across metabolic and other areas of biology, and the enzyme itself is a legitimate subject of ongoing academic interest.
What does not exist is human evidence. There is no published randomised controlled trial of 5-Amino-1MQ in people establishing what it does, at what exposure, or with what safety profile over time. That absence is the single most important fact about this compound, and it is systematically omitted from the marketing that surrounds it.
It also deserves saying that fat-mass findings in rodents have an unusually poor record of translating to humans. Obesity research is littered with compounds that reduced fat mass impressively in mice and then did nothing, or did something unacceptable, in human trials. Mice differ from people in metabolic rate, in fat tissue biology, in thermoregulation and in how their laboratory diets model human eating. A mouse fat-mass result is a reason to run a human trial. It is not a preview of the result.
Where the evidence stops
No published human trials establish efficacy, safety or exposure for this compound. NNMT is active in multiple tissues, not only fat, so the consequences of inhibiting it broadly and over long periods in humans are unknown. The enzyme sits at a junction of NAD+ metabolism and methyl group handling - both wide-reaching systems - which makes off-target and downstream effects difficult to predict from animal data alone. Whether the compound is meaningfully absorbed and reaches relevant tissues in humans in the way it does in mice has not been established in published work. Online claims describing it as a proven metabolic or fat-loss agent are not supported by the evidence that exists. Legal and regulatory status
5-Amino-1MQ is not an approved medicine anywhere. It holds no marketing authorisation in the UK or elsewhere. It is not an authorised food supplement ingredient in the UK either, and it is typically sold as a research chemical, frequently with a label stating it is not for human consumption. That label is a legal position, not a quality standard.
Material sold this way carries no medicines-grade quality assurance. There is no regulator verifying that the vial contains what the label says, at the stated purity, free of contaminants. Independent testing of research-chemical markets has repeatedly found products that were mislabelled, underdosed or contaminated. With no human trial data and no quality assurance, both what the compound does and what is actually in the container are open questions.
This lesson is educational content only and is not medical advice. 5-Amino-1MQ is not an approved medicine and has no established human evidence base. Nothing here is a recommendation to obtain or use it. Any decision about your health or metabolism belongs with a qualified healthcare professional.
Metabolic and incretin compounds Start with the overview: How research peptides are grouped into families
Related in this classroom The studies behind this page Selective and membrane-permeable NNMT inhibitors reverse high-fat-diet-induced obesity in mice - Biochemical and Biophysical Research Communications, 2018Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction - Diabetes, Obesity and Metabolism, 2024Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.